Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
…, P Parente, M Shackleton, W Hopkins… - Proceedings of the …, 2004 - National Acad Sciences
NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a
saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-…
saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-…
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer
…, G Wiseman, S Welt, A Adjei, FT Lee, W Hopkins… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of this research was to determine the safety, immunogenicity,
pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-…
pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-…
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
…, AMT Poon, W Hopkins… - Proceedings of the …, 2007 - National Acad Sciences
An array of cell-surface antigens expressed by human cancers have been identified as
targets for antibody-based therapies. The great majority of these antibodies do not have …
targets for antibody-based therapies. The great majority of these antibodies do not have …
Regulatory T-cell–mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma
…, B Tan, E Maraskovsky, L Miloradovic, W Hopkins… - Clinical Cancer …, 2009 - AACR
Purpose: NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies,
making it an excellent target for cancer vaccination. We recently developed a vaccine …
making it an excellent target for cancer vaccination. We recently developed a vaccine …
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake
AM Scott, FT Lee, R Jones, W Hopkins… - Clinical Cancer …, 2005 - AACR
Purpose: To determine the in vivo characteristics of huA33, a CDR-grafted humanized
antibody against the A33 antigen, we have conducted an open-label, dose escalation, biopsy-…
antibody against the A33 antigen, we have conducted an open-label, dose escalation, biopsy-…
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
M Shackleton, ID Davis, W Hopkins, H Jackson… - Cancer Immunity, 2004 - AACR
Dendritic cells (DCs) show promise as adjuvants in anticancer immunotherapeutic strategies.
Flt3 ligand (FL) is a hematopoietic growth factor that increases the number of immature …
Flt3 ligand (FL) is a hematopoietic growth factor that increases the number of immature …
Phase I biodistribution and pharmacokinetic study of Lewis Y–targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
…, N Micallef, ST Lee, T Saunder, W Hopkins… - Clinical Cancer …, 2009 - AACR
Purpose: This phase I study explored the biodistribution and pharmacokinetics of the
immunoconjugate CMD-193 [a humanized anti–Lewis Y (Le y ) antibody conjugated with …
immunoconjugate CMD-193 [a humanized anti–Lewis Y (Le y ) antibody conjugated with …
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
…, KA Masterman, W Hopkins… - Proceedings of the …, 2004 - National Acad Sciences
There is increasing evidence showing the involvement of CD4 + T cells in initiating and
maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not …
maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not …
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
…, P Parente, T Cavicchiolo, W Hopkins… - Journal of …, 2006 - journals.lww.com
Flt3 ligand mobilizes dendritic cells (DCs) into blood, allowing generation in vivo of large
numbers of DCs for immunotherapy. These immature DCs can be rapidly activated by soluble …
numbers of DCs for immunotherapy. These immature DCs can be rapidly activated by soluble …
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a …
PURPOSE: KM871 is a chimeric monoclonal antibody against the ganglioside antigen GD3,
which is highly expressed on melanoma cells. We conducted an open-label, dose …
which is highly expressed on melanoma cells. We conducted an open-label, dose …